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Simple Summary: In Glioblastoma (GB), a malignant tumor of the central nervous system, diagnosis
can currently only be obtained via tissue biopsy. In this study we were able to isolate GB derived
extracellular vesicles (EVs) in the blood, after patients received 5-aminolevulinic acid (5-ALA)
before surgery. This isolation is based on fluorescence caused by the accumulation of fluorescent
protoporphyrin IX (PpIX) in these EVs. We show that these EVs contain various GB-related micro
RNAs. While there are many ways in which our technique needs to be improved before being able to
be implemented in the clinic, this study shows that detecting and analyzing circulating GB-derived
EVs based on PpIX fluorescence is feasible. In the future, our technique could be developed to
diagnose and monitor GB via blood samples instead of a brain biopsy.
Abstract: Background: In glioblastoma (GB), tissue is required for accurate diagnosis and subtyping.
Tissue can be obtained through resection or (stereotactic) biopsy, but these invasive procedures
provide risks for patients. Extracellular vesicles (EVs) are small, cell-derived vesicles that contain
miRNAs, proteins, and lipids, and possible candidates for liquid biopsies. GB-derived EVs
can be found in the blood of patients, but it is difficult to distinguish them from circulating
non-tumor EVs. 5-aminolevulinic acid (5-ALA) is orally administered to GB patients to facilitate
tumor visualization and maximal resection, as it is metabolized to fluorescent protoporphyrin IX
(PpIX) that accumulates in glioma cells. In this study, we assessed whether PpIX accumulates in
GB-derived EVs and whether these EVs could be isolated and characterized to enable a liquid
biopsy in GB. Methods: EVs were isolated from the conditioned media of U87 cells treated with
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5-ALA by differential ultracentrifugation. Blood samples were collected and processed from healthy
controls and patients undergoing 5-ALA guided surgery for GB. High-resolution flow cytometry
(hFC) enabled detection and sorting of PpIX-positive EVs, which were subsequently analyzed by
digital droplet PCR (ddPCR). Results: PpIX-positive EVs could be detected in conditioned cell culture
media as well as in patient samples after administration of 5-ALA. By using hFC, we could sort
the PpIX-positive EVs for further analysis with ddPCR, which indicated the presence of EVs and
GB-associated miRNAs. Conclusion: GB-derived EVs can be isolated from the plasma of GB patients
by using 5-ALA induced fluorescence. Although many challenges remain, our findings show new
possibilities for the development of blood-based liquid biopsies in GB patients.
Keywords: glioblastoma; 5 aminolevulinic acid; protoporphyrin IX; extracellular vesicles; high-resolution
flow cytometry
1. Introduction
In adult patients, glioblastoma (GB) is the most common primary malignancy of the central
nervous system, with a dismal prognosis [1,2]. Even with extensive treatment including maximal
neurosurgical resection, chemo- and radiotherapy, median survival is approximately 15 months
after initial diagnosis, which has scarcely improved since the introduction of Temozolomide over
a decade ago [3].
One of the many challenges faced by GB treatment and research, is that access to the tumor
is difficult. Definitive diagnosis still requires tissue, which can only be acquired via (stereotactic)
biopsy or neurosurgical resection of the tumor. Although surgical resection is essential to extend the
progression-free period in glioblastoma patients, both stereotactic biopsies and more extended surgical
approaches are associated with significant morbidity and mortality [4–6]. For example, complications
were reported after stereotactic intracranial biopsies in 12.1% of cases in one study, with a 3.8%
overall mortality [4]. This makes repeated biopsies for follow-up or research purposes currently
unjustifiable, even more so as the morbidity and mortality of these procedures increases with successive
procedures [7]. There are also concerns regarding the effects of a biopsy on tumor pathophysiology
itself, as studies have shown increased proliferation and migration of tumor cells after tumor biopsy,
which included accelerated tumor growth in some cases [8,9]. Finally, the concept of determining
therapy from a biopsy taken from a single location in the tumor may not accurately represent the
tumor’s molecular characteristics, as many studies have shown immense heterogeneity throughout
a GB, even on the single cell level [10,11].
There is a strong need for safely acquired and accurate information about the tumor molecular
characteristics. Moreover, analysis of longitudinal samples would provide much needed insights in
therapy responses and could provide opportunities to identify novel therapeutic targets. Today, disease
progression and response to therapy can only be monitored by imaging techniques such as MRI, CT,
and PET CT. Although these techniques can provide information about changes in a tumor mass,
they too possess technique-specific drawbacks. For example, these imaging techniques are–to date–not
able to reliably distinguish true tumor progression from pseudo-progression. Pseudo-progression
is a phenomenon observed on MRI in 10–20% of patients during treatment of glioblastoma with
Temozolomide and radiotherapy [12]. Therapy induced necrosis of glioma and endothelial cells causes
edema and abnormal vessel permeability, mimicking tumor progression, which is indistinguishable
from actual residual tumor growth. There is a great need for a reliable way to distinguish these
two processes, as the different underlying conditions warrant different treatments. In addition, imaging
techniques do not allow for assessment of changes in the molecular profile of a GB that have been shown
to change in response to therapy or in the case of tumor recurrence [13,14]. The relative inaccessibility
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of the tumor hinders accurate follow-up of the molecular changes in GB during and after therapy,
limiting our ability to adequately adapt our therapy.
One way to fulfill the need for longitudinal tumor sampling while minimizing risk of the
patient is via liquid biopsies [15]. Analysis of tumor-derived EVs found in bodily fluids such as
blood or cerebrospinal fluid (CSF), is a promising, minimally invasive, liquid biopsy strategy [16,17].
EVs are lipid bilayer enclosed structures of ~50–200 nm that bud from the cell membrane or are
secreted from multi-vesicular endosomes [18,19]. The molecular cargo of EVs includes proteins, lipids,
and RNA mimicking the phenotype of the releasing cell [20,21]. Cancer cells seem to be typically adept
at releasing EVs and so-called oncosomes, large EVs shed from cancer cell membrane [22]. Analysis of
circulating tumor EVs may therefore enable GB subtyping at the level of the whole tumor rather than
the biopsied area alone [23]. Various efforts are being undertaken to use EVs isolated from blood or
cerebrospinal fluid (CSF) as a biomarker in GB [24]. Although promising, one technical challenge is
to identify and characterize the low number of tumor-derived EVs present in body fluids. Blood of
a healthy volunteer contains approximately 1010 circulating EVs per ml plasma and these EVs are
derived from many different cell types [25]. It has been shown that GB-derived EVs are present in the
circulation, but the number of GB-derived EVs in the blood is probably low [26,27]. Strategies to detect
and isolate GB-derived EVs are therefore required to further analyze the molecular contents of these
tumor specific EVs.
Here we present an approach to detect, sort and characterize GB-derived EVs by using
5-aminolevulinic acid (5-ALA) induced fluorescence. 5-ALA (Gliolan), is an United States Food
and Drug Administration (FDA) approved drug that is used to distinguish GB tissue from normal
tissue during surgery. 5-ALA, a precursor to heme, is orally administered to the patient before surgery
and taken up by glioma cells, where it is metabolized to fluorescent protoporphyrin IX (PpIX) in the
mitochondria [28]. PpIX then accumulates in glioma cells due to decreased levels of ferrochelatase
and selective uptake by ATP-binding cassette transporter ABCB6 [29]. Upon excitation with 405 nm
wavelength light, the elevated levels of PpIX in glioma cells causes them to fluoresce in bright violet-red,
enabling easier identification of malignant tissue during surgery to improve the chance of maximal
surgical resection [30].
We show that administration of 5-ALA induces accumulation of PpIX in GB-derived EVs.
This increased fluorescence in GB-derived EVs is detectable by high-resolution flow cytometry and
allows for the detection of tumor EVs in the plasma of GB patients. Using advanced high-resolution
flow cytometric sorting, we can isolate PpIX-positive EVs from the plasma of GB patients. With digital
droplet PCR, we can detect tumor specific micro-RNAs in as few as 5 sorted PpIX-positive EVs.
Our data illustrates the possibilities and limitations for fluorescent EV-based liquid biopsies in
GB patients.
2. Materials and Methods
2.1. Platelet-Free Plasma Sample Processing
This study was approved by the ethics review committee of UMC Utrecht (protocols 18-020
and 18-021). Blood samples from 30 patients suspected of GB were collected. Per hospital protocol,
5-ALA was given orally 3 h before the start of surgery at a dose of 20 mg/kg. Before start of the
surgery, arterial whole blood was taken in citrate buffered collection tubes and kept in the dark to avoid
fluorescent quenching. The blood was then centrifuged at 1500× g for 10 min at room temperature.
After the centrifugation, the top fraction of plasma was pipetted in standard 1.5 mL Eppendorf tubes
and centrifuged at 13,000× g for 10 min at room temperature. The supernatants were then pooled,
homogenized, and aliquoted in 1.5 mL Eppendorf tubes and stored at −80 ◦C for later use.
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2.2. Cell Culture and Microscopy
The established cell line U87-MG/EGFRvIII (MG: Malignant Glioma, human GB cell line)
was cultured in Dulbecco’s modified Eagle’s medium (DMEM) (Invitrogen, Carlsbad, CA, USA)
containing 10% fetal bovine serum (FBS; Invitrogen) supplemented with penicillin (100 units mL−1) and
streptomycin (100 µg mL−1; Invitrogen). The authenticity of the cell line was confirmed by short tandem
repeat (STR) analysis, using the AmpFLSTR Identifiler PCR Amplification Kit (Applied Biosystems,
Foster City, CA, USA). 24 h before microscopic experiments or EV isolation the medium was changed
to medium without FBS and a 500 µM 5-ALA (Sigma-Aldrich, Darmstadt, Germany) concentration
consisting of DMEM without phenol-red (Lonza, Basel, Switzerland) supplemented with penicillin
(100 units mL−1) and streptomycin (100 µg mL−1; Invitrogen) and ultraglutamine (Lonza). All cell
cultures were maintained at 37 ◦C in a humidified atmosphere of 5% CO2. For microscopic analysis
1.76 × 104 cells were plated in chambered covered glass slides (Lab-Tek II) and placed on Zeiss Axiovert
200 M microscope using a set-up with 490–510 nm excitation and a dichroic BP585 nm emission filter
(590–650 nm).
2.3. EV Isolation
A total of 1.54× 106 cells were plated in 15 cm cell culture plates for 24 h in complete FBS containing
medium, after which the medium was switched to the 5-ALA containing medium described above
and the cells were cultured for another 24 h. The supernatant was then collected and centrifuged at
300× g for 10 min to remove cellular debris. The subsequent supernatant was centrifuged at 2000× g for
10 min and then loaded in ultracentrifuge tubes and centrifuged at 100,000× g for 70 min (SW32 rotor,
Beckman Coulter, Pasadena, CA, USA) after which the pellet was resuspended in phosphate buffered
saline (PBS) and loaded in smaller ultracentrifuge tubes (SW41 rotor, Beckman Coulter, Brea, CA, USA)
and centrifuged for an additional 70 min at 100,000× g. The EV containing pellet was then resuspended
in PBS, aliquoted and stored at stored at −80 ◦C for later use. As PpIX signal is known to be susceptible
to photobleaching [31], cells and samples were processed in the dark or under low light conditions as
much as possible.
2.4. Tunable Resistive Pulse Sensing
EVs were quantified using tunable resistive pulse sensing as described before [32,33]. In brief,
isolated EVs were diluted 1:10 in PBS and then loaded onto the qNano instrument (Izon Science Ltd.,
Christchurch, New Zealand). The samples were measured in duplicate alternating with 203 nm
polystyrene calibration beads using an NP100 crucifix. Data was recorded and analyzed using the
Izon Control Suite Software. The default minimum blockade height (0.05 nA) for particle detection
was used.
2.5. High-Resolution Flow Cytometry
High-resolution flow cytometry of EVs was performed on a jet-in-air-based Becton Dickinson
Influx flow cytometer (BD Biosciences, San Jose, CA, USA) using an optimized configuration as
previously described in detail [34,35]. For experiments presented in this study, only the 405 nm laser
was used. The optical configuration was modified to allow the collection of forward scattered light
(FSC), side scattered light (SSC), and fluorescence off the 405 nm laser. To that end, a 405/20 bandpass
filter was placed in front of the FSC detector combined with a 5 mm obscuration bar in front of the
FSC collection lens to reduce excessive optical background [35]. Both PpIX fluoresce and SSC were
collected at a 90 degree angle and in this direction a 480 long pass dichroic mirror was placed to
reflect the shorter wavelength to the SSC detector equipped with a 405/20 bandpass and a neutral
density (ND) filter. The PpIX fluorescence passed the dichroic mirror to reach a photomultiplier tube
(PMT)equipped with a 630/22 bandpass filter. All scatter and fluorescence parameters were set to log
scale. The PpIX fluorescence was used as a trigger signal and a threshold was set to reduce background
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signal (background set at less than 50 events per second) using clean PBS samples for cell culture EV
(Figure 1), or healthy platelet-free plasma diluted 1:300 in PBS for detection of PpIX-positive EV in
plasma (Figures 2 and 3). The alignment of the Influx was performed using 8 peak Rainbow Calibration
Particles (Biosciences, Erembodegem, Belgium). For high-resolution analysis of the samples, a nozzle
with a bore size of 140 µM was used. Pressure of sheath (4.89–5.02 PSI) and sample (4.29 PSI) were kept






























































Figure 1. Administration of 5-ALA leads to PpIX fluorescence in vitro and in vivo. (A) Intra-operative
view of Glioblastoma resection under white light (top row) and under 405nm light (bottom row).
Protoporphyrin IX (PpIX) fluorescence is seen as pink. (B) U87 cells treated with 5-aminovulenic
acid (5-ALA) (left panels) show PpIX fluorescence upon excitation at 490nm compared to control
(right panels). 40×magnification. (C) Tunable resistive pulse sensing (TRPS) analysis of EVs isolated
from U87 cells treated with 5-ALA. n = 2 (D) TRPS analysis of EVs isolated from U87 cells treated with
PBS control. n = 2. (E) High-resolution flow cytometry (hFC) analysis of PBS. (F) hFC analysis of PBS
with EVs isolated from U87 cells. (G) hFC analysis of PBS with EVs isolated from U87 cells treated
with 5-ALA.
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Figure 2. Isolation of PpIX-positive EVs from patient plasma. (A) Centrifugation protocol for the isolation
of platelet-free plasma from whole blood. (B) hFC analysis of platelet-free plasma. (C) hFC analysis of
platelet-free plasma spiked with 2× 107 U87 derived PpIX-positive EVs. (D) hFC analysis of platelet-free
plasma spiked with 1 × 108 U87 derived PpIX-positive EVs. (E) Linear regression plot of the % of
particles in the PpIX gate versus the number of PpIX EVs spiked in. Goodness of fit, R2: 0.9998. (F) hFC
analysis of PpIX particles in platelet-free plasma from control (10 min measurement). (G) hFC analysis
of PpIX particles in platelet-free plasma from a patient treated with 5-ALA (10 min measurement).
(H) Number of particles in the PpIX gate per patient group detected during 5 min of measurement.
All samples were prepared in PBS. Platelet-free plasma samples were diluted 1:300 prior to analysis.
All samples were measured in a fixed time window (30 s for EVs from in vitro cultured cells and 300 s
for plasma sample) to allow for comparison of EV numbers between samples. To calculate the number
of PpIX-positive events in plasma samples, a gate was placed based on SSC and PpIX fluorescence
values or SSC-PpIX fluorescence allowing a maximum of 10 events in this gate for healthy plasma run
as a control. Measurements were performed using BD FACS Software 1.01.654 (BD Biosciences).






















































































































Figure 3. ddPCR analysis of PpIX-positive EVs. (A) Number of copies of miR-21 found in the
indicated number of sorted PpIX-positive EVs from U87 cells treated with 5-ALA. EVs isolated
by ultracentrifugation were diluted in PBS and sorted with high-resolution flow cytometry.
NTC: non-template control. EVs: extracellular vesicles. (B) Number of copies of miR-21 found
in the indicated number of sorted PpIX-positive EVs from U87 cells treated with 5-ALA. EVs were
isolated by ultracentrifugation, diluted in healthy donor plasma, and sorted with high-resolution flow
cytometry. (C) Number of copies of miR-21 in PpIX-positive EVs sorted from a patient with GB after
receiving 5-ALA. (D) Number of copies of miR-10b in PpIX-positive EVs sorted from a patient with GB
after receiving 5-ALA. (E) Number of copies of Let-7a in PpIX-positive EVs sorted from a patient with
GB after receiving 5-ALA.
2.6. High-Resolution Flow Cytometric Sorting of EVs
For sorting experiments, the system and procedure were optimized to allow for maximal event
rates and small sort volumes, but to avoid coincidence [36]. In short, a 70 µm nozzle was used
and sheath fluid pressure increased to 30 psi. At a sample fluid pressure of 29 psi, an event rate of
≤5000 per second was reached (higher event rates resulted in coincidence and swarm). The drop
frequency was 49.22 kHz with sort efficiencies of approximately 95%. Drop delay was adjusted using
Accudrop beads (Cat nr.: 345249 BD Biosciences). Drop delay time was cross checked by sorting these
beads on microscope glass slides using the coarse calibration slide sorting mode of the BD Influx and if
necessary adjusted to the proper delay time. For EV sorting, plasma samples were diluted 1:300 in PBS.
Sorted EVs were collected in 96 well plates at 5 to 320 EV per well. The volume of one sorted drop was
calculated to be 2 nl.
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2.7. Measurement of miRNA Levels from Sorted EVs
Reverse transcription was performed using the TaqMan miRNA Reverse-Transcription Kit and
miRNA-specific stem-loop primers (Applied BioSystems) in a 15 µL RT reaction (comprised of 8.56 µL
of H2O, 1.5 µL of 10× Reverse-Transcription Buffer, 0.19 µL of RNase-Inhibitor (20 units/L)), 1 µL of
100 mM dNTPs with dTTP, 1 µL of Multiscribe Reverse Transcriptase, and 3 µL RT primer [miR16
(RT:000391); miR10b (RT:002218); let7a (RT:000377); miR21 (RT:000397); Catalog: 4427975 Thermofisher].
These components are prepared as a larger master mix and 14.4 µL of master mix is added to each well
of a 96 well plate with the sorted EVs and mixed well by pipetting. RT reactions are carried out in
a Tetrad2 Peltier Thermal Cycler (Bio-Rad, Hercules, CA, USA) at 16 ◦C for 30 min, 42 ◦C for 30 min
and 85 ◦C for 5 min and held at 4 ◦C. For droplet digital PCR analysis, 5 µL of cDNA was added to the
reaction mixture containing 10 µL of 1× ddPCR Supermix for probes (no dUTP, Bio-Rad), 1 µL of probes
20× primer [miR16 (TM:000391); miR10b (TM:002218); let7a (TM:000377); miR21 (TM:000397); Catalog:
4427975 Thermofisher] and 4 µL of water to yield a total reaction volume of 20 µL. The QX200 AutoDG
Automatic Droplet generator (Bio-Rad) was used to generate droplets. Thermocycling conditions were
as follows: 95 ◦C (51% ramp) for 10 min, 40 cycles of 94 ◦C (51% ramp) for 30 s and 60 ◦C for 1 min,
followed by 98 ◦C for 10 min and held at 4 ◦C until further processing. Droplets were counted and
analyzed using the QX200 droplet reader (Bio-Rad) and QuantaSoft analysis (Bio-Rad) was performed
to acquire data and later normalized to the input.
2.8. Statistical Analysis
Graphing and statistical analysis was done in Prism version 8.3.0 (Graphpad Software LLC,
San Diego, CA, USA). Figures were prepared in Adobe Illustrator 2019 (Adobe Systems, San Jose,
CA, USA).
3. Results
3.1. Administration of 5-ALA Leads to Accumulation of Fluorescent PpIX in EVs
Prior to neurosurgery, GB patients are administered 20 mg/kg 5-ALA orally. In most patients,
tumor cells can be detected during surgery by their fluorescent pinkish glow upon excitation with
a 405 nm laser (Figure 1A). To replicate this effect in vitro, we cultured human glioma U87-MG/EGFRvIII
cells in vitro with or without 5-ALA. We selected 500 µM as an optimal 5-ALA concentration at which
cells were efficiently labeled and remained viable (data not shown). This is in line with previous
publications on 5-ALA labeling of in vitro cultured cells [28,31]. As expected, accumulation of
fluorescent PpIX could be detected in cells treated with 5-ALA for 24 h (Figure 1B). To evaluate
whether PpIX also accumulates in EVs, we isolated EVs from the supernatant of the cultured cells by
differential centrifugation. Using tunable resistive pulse sensing (TRPS) we could detect particles in the
100–200 nm size range, as expected for EVs [32,37]. Similar size distribution and EV concentrations were
observed from both the 5-ALA treated cells as for the mock control cells (Figure 1C,D). To determine
if EVs harbor fluorescent PpIX, both the mock control and 5-ALA treated EVs were analyzed by
high-resolution flow cytometry (hFC) [34,35] by thresholding on the PpIX fluorescence signal. Our data
indicated that EVs from 5-ALA treated cells contained sufficient fluorescence to be detected above the
fluorescence threshold, while EVs from the control cells were not detectable (Figure 1E–G). Together,
these results indicate that treatment of in vitro cultured glioma cells with 5-ALA can induce the loading
of fluorescent PpIX in glioma cell-derived EVs. Individual PpIX-positive EVs can be detected using
high-resolution flow cytometry.
3.2. PpIX-Positive EVs Can Be Detected in the Plasma of Glioblastoma Patients
Until now, hFC has only been applied to analyze EVs that were labeled after purification from
body fluids. Our next goal was to evaluate whether hFC could be used to detect individual PpIX EVs
against the background of unfractionated patient plasma. Plasma is a protein-rich fluid that contains
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many macromolecular structures such as lipoparticles. All these structures likely contribute to the
background signals during hFC. To optimize hFC settings, we used platelet-free plasma isolated from
whole blood from healthy donors via centrifugation (Figure 2A). Fluorescence threshold triggering
was applied on the channel used to detect PpIX fluorescence. We first performed serial dilution of the
plasma to find the dilution at which hFC analysis was not affected by (invisible) swarm [38]. We raised
the threshold until less than 50 background events per second were visible. Next, we analyzed plasma
samples in which we spiked different numbers of U87-5ALA EVs. Single PpIX-positive particles could
be detected above the background signal in a dose dependent manner (Figure 2B–E).
To determine if PpIX-positive particles could be detected in the platelet-free plasma of GB
patients, we collected samples from patients who underwent surgery for suspected GB using 5-ALA as
an intra-operative tool. In this group, two GB patients undergoing surgery without the use of 5-ALA
were also included. Two other patients underwent 5-ALA assisted surgery, but histopathological
analysis of the suspected mass did not show the presence of malignant cells (one patient was diagnosed
with a chronic inflammation and one patient with radiation induced changes). These two groups were
used as controls. All other included patients had either primary or recurrent WHO IV glioblastoma,
as determined by post-operative histopathological analysis. All patients with recurrent GB had
previously been treated according to the Stupp protocol [39] (resection followed by 6 weeks of
radiotherapy (total of 60 Gy)) combined with Temozolomide (75 mg per square meter body-surface
area), followed by six cycles of adjuvant Temozolomide (150 to 200 mg of Temozolomide per square
meter for 5 days during each 28 day cycle). Additional patient characteristics can be found in Table S1.
Blood was collected after 5-ALA administration, just before start of the surgery. The number of
PpIX-positive EVs was low with 5–60 EVs per patient collected during an acquisition time of 300 s in
which a total of 1 ul of plasma diluted in PBS was analyzed. The number of positive events varied
widely between samples, with one control having a considerate number of particles in the PpIX gate
(Figure 2H). We had limited data on radionecrosis, but this also appeared to enhance PpIX fluorescence.
The number of PpIX-positive particles was highest in patients with recurrent GB. Figure 2F,G illustrate
the detection of PpIX-positive EVs in a healthy control and patient sample, ran for a longer time period
than the patients in Figure 2H for illustrative purposes. These data suggest that PpIX-positive EVs can
be detected in patient plasma with GB but that the levels are highly variable.
3.3. PpIX-Positive EVs Isolated by High-Resolution Flow Cytometric Sorting Contain GB-Associated miRNAs
We previously showed that our hFC system allows sorting of single EVs harboring fluorescence
or light scattering characteristics of interest [36,40]. The number of PpIX-positive, GB-derived EVs in
patient plasma is low (Figure 2H). Using high-resolution flow cytometric sorting (see Figure S1B,C for
the gating strategy), we were able to isolate PpIX-positive vesicles, To further evaluate these particles,
we performed ddPCR for several GB-associated and EV associated miRNAs on the isolated particles.
To test the feasibility of detecting tumor-related miRNAs in the low numbers of sorted EVs, we first
sorted increasing numbers of PpIX-positive EVs (5–320 EV) from 5-ALA treated U87-MG/EGFRvIII
cells in a 96 well plate and performed ddPCR for miR-21 (Figure 3A). We were able to detect copies of
miR-21 in as little as five EVs. We then spiked PpIX-positive EVs from 5-ALA treated U87-MG/EGFRvIII
cells into plasma from a healthy donor and sorted increasing numbers of EVs for ddPCR analysis.
The number of detected miR-21 copies in these EV isolates was more variable, but signal was detectable
above negative control levels (Figure 3B). Sorting higher numbers of EV per sample led to a decrease,
rather than an increase, in the number of detected miRNA copies (Figure S1D,E). We speculate that
the increased volume of buffer in which higher numbers of EVs are sorted interferes with the RNA
isolation efficiency and/or ddPCR.
After optimizing our set-up we quantified the presence of three miRNAs in PpIX-positive EVs
sorted from a GB patient treated with 5-ALA. miR21, an antiapoptotic factor, is highly expressed in
GB [41] and GB EVs [42] as is miR10b, which is associated with tumor invasive properties and glioma
growth [43,44]. Let7a is aberrantly expressed in GB and can be used as a marker for EVs [45,46].
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We confirmed that multiple copies of these miRNAs could be detected in the PpIX-positive EVs of a GB
patient treated with 5-ALA (Figure 3A). Although the levels of the miRNAs detected in the EVs were
low and variable, the signal was above the control (no template control, NTC). No clear relationship was
observed between the number of EVs sorted and the miRNA copy number. The heterogeneity of EVs
and their cargo could explain this observation [20], but certain technical limitations may also play a role.
This data shows that hFC sorting of EVs and subsequent analysis with ddPCR is feasible, illustrating
the potential of this method in identifying circulating GB-derived EVs based on PpIX fluorescence.
4. Discussion
For several years, 5-ALA has been used in GB patients for intra-operative tumor tissue
visualization [28,47]. Here we show that after administration of 5-ALA, PpIX accumulates in glioma
derived EVs both in the media of cell cultures and in the plasma of GB patients. Using high-resolution
flow cytometry, we were able to detect and isolate PpIX-positive, GB-derived EVs. Sorting these EVs
allowed us to analyze their contents, which confirmed the presence of GB specific miRNA miR-21 [41],
miR-10b [43] and EV specific miRNA (let-7a) [46].
Given the challenges associated with (repeated) surgery for tissue diagnosis, establishing a reliable
liquid biopsy technique is a major goal in glioma research. Various approaches are being explored,
including isolation of circulating tumor cells (CTCs), circulating tumor DNA, and EVs [15]. EVs may be
more suitable as biomarkers for glioblastoma as they are more abundant than CTCs [48] and because
the genetic content of EVs is relatively more stable compared to circulating DNA due to enclosure in
lipid bilayers [49]. The major challenge is to isolate GB-derived EVs from the billions of circulating
particles in the blood [25]. Most attempts to isolate GB-derived EVs from the circulation include
selection of EVs by capturing specific surface proteins [50]. So far none of these approaches have made
it into clinical practice and recent evidence that the ectodomain of EV-surface receptors can be cleaved
off may further complicate this approach [51].
We investigated an approach of using a byproduct of a clinically approved drug currently used
during glioma surgery to detect EVs in the circulation of GB patients. The idea that oral administration
of 5-ALA might lead to not only PpIX accumulation in tumor cells but also in tumor-derived EVs has
been proposed previously [52]. Recently, Jones et al. showed that PpIX-positive EVs are released by
glioma cells treated with 5-ALA in vitro, and can be detected in the plasma of glioma xenograft mice
and patients who had been administered 5-ALA prior to surgery, using imaging flow cytometry [53].
Here, we show for the first time the ability to not only detect these PpIX-positive EVs, but also to isolate
them using high-resolution flow cytometric sorting for downstream analysis. This is a major step in
the development towards liquid biopsies in GB to isolate the tumor specific EVs and to decrease the
necessity of high throughput modalities such as next-generation sequencing for analysis.
Before this technique can be applied at a larger scale, several technical hurdles need to be overcome.
The signal-to-noise ratio for hFC-based detection of PpIX-positive particles against background signals
from plasma is low. This may explain why even in patients that did not receive 5-ALA, some positive
particles are detected. Reduction of plasma protein background could be achieved by including a size
exclusion chromatography step, but potential loss of PpIX-positive EVs in the column would impose
a substantial risk to reduce accuracy in the rare event analysis. Our high-resolution flow cytometry
approach did not provide information on the total number of EV in the sample, as particles were only
registered if their PpIX fluorescence exceeded the threshold set by the user. The percentage of PpIX
EVs respective to the total number of EVs could therefore not be measured, but instead an absolute
number of positive events in a volume or run time was obtained. It should also be noted that the gating
and sorting of the PpIX-positive EVs is tedious and strict protocols should be followed to prevent
swarm effects, which can interfere with the results [36].
Large variability was observed in the number of detectable PpIX-positive EVs between patients
and controls. PpIX-positive particles were observed in two patients who did not receive 5-ALA prior
to surgery, but who did have active GB. As we know that PpIX accumulation occurs in GB and 5-ALA
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exacerbates this effect, it could be that even without 5-ALA some particles fluoresce with PpIX. As our
technique is extremely sensitive, it is possible that we pick up these few particles. Another explanation
can be found in several (rare) syndromes that have been linked to PpIX accumulation without 5-ALA
administration, such as X-linked protoporphyria and human erythropoietic protoporphyria [54].
More common mechanisms such as iron deficiency and the use of nonsteroidal anti-inflammatory
drugs have also been linked to PpIX accumulation in cells [55]. In patients who did receive 5-ALA,
PpIX fluorescence can also occur in non-tumor tissue [56,57]. One study showed that in 13 out of
313 cases operated on for recurrent GB, the PpIX fluorescent material that was resected showed only
reactive tissue with notable edema, inflammatory cell infiltration and presence of reactive astrocytes [57].
In the two patients who turned out to have radio necrosis in our cohort, we also picked up PpIX-positive
particles, supporting this data. Radionecrosis, disruption of the blood-brain barrier and infiltration of
inflammatory seemed to play a role in this process, but the exact relation with accumulation of PpIX in
EVs remains to be understood. Given the various possible sources of PpIX-positive EVs, it is possible
that some of the particles we observed in patients with GB are derived from non-GB tissues. However,
the presence of the GB enriched miR-21 and miR-10b suggests that these particles have GB origin.
EVs are known to contain very little miRNAs, averaging less than one non-ribosomal RNA per EV [58].
The presence of miR-21 and miR-10b, both highly expressed in GB but not in normal tissue [41–43],
could be an indicator for GB origin. To provide a more complete overview and comparison, we aim
to further analyze PpIX-positive EVs from GB patients and non-GB patients in future studies with
various newer sequencing techniques.
Our in-house developed method to perform hFC-mediated sorting of single EVs in ultra-low
volumes (2 nl drop volume) allowed for ddPCR analysis on exact numbers of collected EVs. The copy
number of miR-21 in EVs isolated from U87 cells roughly resembled the number of EVs sorted,
while in patient data the number of miRNA copies was much more variable (Figure 3). Although it is
possible that the quantitative sorting process was not 100% accurate, another likely explanation is that
the population of PpIX-positive EVs is heterogeneous in volume and molecular cargo. EVs derived
from U87 cells in vitro are likely more homogeneous in content compared to those from patient
gliomas. Heterogeneity is a common feature of EV populations derived from glioma patients [20,59,60],
as is heterogeneity of glioma tissue itself [10]. Furthermore, the EVs measured in vitro varied in
diameter from 100 to 200 nm. For spherical EVs, this implies a difference in volume of factor 8 between
the largest and smallest EVs detected. As a result, the small groups of individually sorted EVs may
contain variable copy numbers of the tested miRNAs and, in the limited number of EVs sorted,
a linear relation between EVs and copy numbers is not to be expected. Our efforts to analyze a larger
number of EVs with ddPCR were limited due to a loss of signal with increased input (Figure S1D,E).
It is vital that these techniques for downstream analysis are optimized in future studies. Additionally,
improved ddPCR analysis could serve as a secondary method to detect ‘false positives’, EVs that were
PpIX-positive but did not have a GB origin.
The number of PpIX fluorescent particles in GB patients differed widely. Part of this variation
may be explained by differences in tumor fluorescence, which depends on many variables, including
time between 5-ALA administration and surgery, necrosis [28], glioma subtype [61] and proliferation
index [62]. To what extent these factors contribute to the number of PpIX-positive events remains to be
elucidated, as our study was underpowered to evaluate these variables. Furthermore, PpIX signal
bleaches quickly under white light [31,53], so precautions have to be taken to prevent loss of signal.
We evaluated the change in signal in respect to time from sample collection to EV isolation, but found
no negative correlation. More reliable results may also be obtained by comparing the number of
PpIX-positive particles in plasma samples from patients collected during surgery to the number
observed in pre-surgery samples, which can be used as in-patient controls [53]. In future studies,
more controls and patient data should be obtained to evaluate whether other factors could cause EVs to
carry a PpIX(-like) signal. Given the sensitivity of PpIX fluorescence to bleaching, we applied stringent
standardization of blood acquisition with rapid plasma processing, as these steps may influence the
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number of background events. We strongly encourage researchers to take these precautions when
working with PpIX fluorescence in GB.
The data presented here illustrate the potential of identifying and sorting PpIX EVs to uncover
differences in expression profile between the various GB cells using GB patient plasma as a liquid biopsy.
5. Conclusions
Our data shows the potential for isolating GB-derived PpIX-positive EVs from plasma after oral
administration of 5-ALA via high-resolution flow cytometric sorting. Although several challenges
remain, we have taken yet another step on the road towards improving GB diagnostics using EVs in
liquid biopsies. With further development and refinement, these techniques will open various avenues
of longitudinal follow-up, disease monitoring, customization of therapy and, possibly, screening
for either recurrence or primary disease in patients at risk. By evading invasive surgical biopsies,
this technique enables researchers to gain new insights in GB pathogenesis and will aid in improvements
of care and treatment for patients suffering from glioblastoma.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/12/11/3297/s1,
Table S1: Patient characteristics, Figure S1: (A) Example of the gating strategy employed for sorting of PpIX-positive
EVs in a healthy control and (B) in a GB patient treated with 5-ALA. (C) ddPCR detailing the number of copies of
miR-21 found in various numbers of U87 EVs sorted from PBS. (D) EVs derived from U87 cells were spiked in
healthy plasma and consequently sorted with high-resolution flow cytometry. ddPCR for miR-21 was performed
on various numbers of EVs.
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